[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Hsing CT, Oh SY, Lee S, Kwon HC, Kim SH, Park TH, Woo JS, Na SH, Kim HJ: Extraskeletal mesenchymal chondrosarcoma of the heart responded to systemic chemotherapy: a case report. Cancer Res Treat; 2007 Sep;39(3):131-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal mesenchymal chondrosarcoma of the heart responded to systemic chemotherapy: a case report.
  • Mesenchymal chondrosarcoma is a rare cartilaginous neoplasm of an extraskeletal origin, and this predominately occurs in the head and neck, and also in the lower extremities.
  • For the most part, the results of treatment for patients with this condition have been dismal.
  • In this study, we describe a case of cardiac mesenchymal chondrosarcoma that responded to chemotherapy following surgical biopsy.
  • Chest computed tomography revealed an ovoid-shaped mass in the posterior wall of the patient's left atrium.
  • Seven days later, a thoracotomy was performed for reduction and diagnosis of the cardiac mass.
  • The pathological diagnosis was extraskeletal mesenchymal chondrosarcoma of the heart..
  • Postoperative chemotherapy was performed for the huge remaining mass with a combined regimen of etoposide, ifosfamide and cisplatin.
  • Although cardiac mesenchymal chondrosarcoma has been reported to be chemotherapy-resistant with a short survival duration, chemotherapy may prove to be an effective treatment modality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2006 Mar;13(3):285-6 [16643625.001]
  • [Cites] Ital Heart J. 2000 Jun;1(6):435-7 [10929746.001]
  • [Cites] Am J Emerg Med. 1996 May;14(3):285-7 [8639204.001]
  • [Cites] Jpn Circ J. 1997 Sep;61(9):795-7 [9293411.001]
  • (PMID = 19746223.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739328
  • [Keywords] NOTNLM ; Extraskeletal / Heart / Mesenchymal chondrosarcoma
  •  go-up   go-down


2. Cleton-Jansen AM, van Beerendonk HM, Baelde HJ, Bovée JV, Karperien M, Hogendoorn PC: Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma. Clin Cancer Res; 2005 Nov 15;11(22):8028-35
Hazardous Substances Data Bank. ANDROSTENEDIONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
  • PURPOSE: Chondrosarcoma is a malignant cartilaginous matrix-producing tumor that can be lethal in 10% to 50% of the patients.
  • Surgery is the only effective treatment known as these tumors are notorious refractory to all types of conventional chemotherapy or radiotherapy.
  • To identify a target for therapy, we want to determine whether estrogen signaling is active in chondrosarcoma because estrogen is important in the regulation of longitudinal growth that is initiated by chondrocyte proliferation and differentiation in the epiphyseal growth plate of long bones.
  • EXPERIMENTAL DESIGN: We studied protein expression of the estrogen receptor in 35 cartilaginous tumors as well as mRNA levels for the estrogen receptor and for aromatase, an enzyme for estrogen synthesis and another potential therapeutic target.
  • This observation implicates potential use of targeted drugs that interfere with estrogen signaling, such as those applied for treating breast cancer.
  • [MeSH-major] Bone Neoplasms / drug therapy. Chondrosarcoma / drug therapy. Estrogen Antagonists / therapeutic use. Estrogens / physiology. Signal Transduction
  • [MeSH-minor] Adult. Aged. Androstadienes / pharmacology. Androstenedione / pharmacology. Aromatase / genetics. Aromatase / metabolism. Aromatase Inhibitors / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Neoplasm Metastasis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Estrogen / genetics. Receptors, Estrogen / metabolism

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16299232.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Aromatase Inhibitors; 0 / Estrogen Antagonists; 0 / Estrogens; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 107868-30-4 / exemestane; 409J2J96VR / Androstenedione; EC 1.14.14.1 / Aromatase
  •  go-up   go-down


3. Feyzi R, Hassan ZM, Mostafaie A: Modulation of CD(4)(+) and CD(8)(+) tumor infiltrating lymphocytes by a fraction isolated from shark cartilage: shark cartilage modulates anti-tumor immunity. Int Immunopharmacol; 2003 Jul;3(7):921-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of CD(4)(+) and CD(8)(+) tumor infiltrating lymphocytes by a fraction isolated from shark cartilage: shark cartilage modulates anti-tumor immunity.
  • Shark cartilage has proven to have some inhibitory effects on angiogenesis, metastasis, cell adhesion and proteolysis.
  • In this study, we wanted to study some of the effects of shark cartilage on tumor immune response.
  • Firstly, by means of chromatographic methods and delayed type hypersensitivity (DTH) test, we optimized a procedure for isolation and purification of a shark cartilage protein fraction with most immunostimulatory effects.
  • Then, we examined its effect on the infiltration of CD(4)(+) and CD(8)(+) lymphocytes into a murine tumor model.
  • Furthermore, intraperitoneal injection of this fraction to tumor-bearing mice could increase T-cell infiltration into the tumor.
  • Also, there was a significant increase in the CD(4)/CD(8) ratio in tumor infiltrating lymphocytes, but no such changes were found in the peripheral blood lymphocytes.
  • According to these results, we suppose that this fraction is a good candidate for further studies in cancer therapy.
  • Also, we concluded that this fraction, with previously proven anti-angiogenic effects, can augment cellular immune response and T-cell infiltration into the tumor and thus, there may be a direct relationship between angiogenesis inhibition and T-cell infiltration.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adjuvants, Immunologic / pharmacology. CD4-CD8 Ratio. Cartilage / chemistry. Mammary Neoplasms, Experimental / drug therapy. Peptides / pharmacology. Sharks

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12810349.001).
  • [ISSN] 1567-5769
  • [Journal-full-title] International immunopharmacology
  • [ISO-abbreviation] Int. Immunopharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Peptides
  •  go-up   go-down


Advertisement
4. Cecchetto G, Alaggio R, Scarzello G, Dall'Igna P, Martino A, Bisogno G, Guglielmi M: Teratoid Wilms' tumor: report of a unilateral case. J Pediatr Surg; 2003 Feb;38(2):259-61
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoid Wilms' tumor: report of a unilateral case.
  • Teratoid Wilms' tumor is a rare histologic variant of the classical Wilms' tumor, containing predominantly heterologous tissues (adipose, glial, muscle, cartilage, or bone).
  • This report presents the case of a teratoid Wilms' tumor in a 4-year-old girl.
  • Despite the enormous dimensions of the tumor and the involvement of the inferior vena cava, a radical excision was obtained, and now the child is well 32 months after surgery.
  • The behavior of this kind of tumor usually is not aggressive, and the outcome is good.
  • Surgery should be the treatment of choice, because the efficacy of chemotherapy and radiotherapy is probably reduced by the high amount of differentiated and mature tissue which characterizes this neoplasm.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Wilms Tumor / pathology. Wilms Tumor / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Radiotherapy, Adjuvant. Teratoma / diagnosis. Teratoma / pathology. Treatment Outcome. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003, Elsevier Science (USA). All rights reserved.
  • (PMID = 12596119.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Giraud I, Rapp M, Maurizis JC, Madelmont JC: Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma. J Med Chem; 2002 May 9;45(10):2116-9
Hazardous Substances Data Bank. CHLORAMBUCIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and in vitro evaluation of quaternary ammonium derivatives of chlorambucil and melphalan, anticancer drugs designed for the chemotherapy of chondrosarcoma.
  • To enhance affinity for malignant cartilaginous tumors (chondrosarcomas), quaternary ammonium (QA) conjugates of chlorambucil and melphalan were prepared by linking the QA moiety to nitrogen mustards via an amide bond.
  • [MeSH-minor] Animals. Chondrosarcoma. Drug Screening Assays, Antitumor. Humans. Melanoma. Mice. Structure-Activity Relationship. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11985479.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quaternary Ammonium Compounds; 18D0SL7309 / Chlorambucil; Q41OR9510P / Melphalan
  •  go-up   go-down


6. Chow WA: Update on chondrosarcomas. Curr Opin Oncol; 2007 Jul;19(4):371-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: This paper reviews recent molecular, biologic, developmental therapeutic, and clinical findings in conventional and variant chondrosarcomas.
  • Translational research has validated platelet-derived growth factor receptor, estrogen signaling, matrix metalloproteinase-1, histone deacetylase, methylthioadenosine phosphorylase, and vascular endothelial growth factor-A as potential therapeutic targets.
  • Clinical studies have shown that development of second malignancies is an uncommon but real risk for chondrosarcoma survivors; the benefit of chemotherapy for dedifferentiated chondrosarcomas remains questionable; and late recurrences of clear cell chondrosarcomas emphasize the need for long-term follow up.
  • SUMMARY: Chondrosarcomas are a heterogeneous group of bone and soft tissue tumors.
  • Recent advances in molecular diagnostics, pathobiology, and developmental therapeutics will aid both scientists and clinicians in improving the classification and therapy of this diverse family of cartilaginous tumors.
  • [MeSH-major] Bone Neoplasms. Chondrosarcoma
  • [MeSH-minor] Biomarkers, Tumor. Evidence-Based Medicine. Humans. Mesoderm. Molecular Diagnostic Techniques. Prognosis. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545802.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


7. Odashiro AN, Leite LV, Oliveira RS, Tamashiro C, Pereira PR, Miiji LN, Odashiro DN, Burnier MN Jr: Primary orbital mesenchymal chondrosarcoma: a case report and literature review. Int Ophthalmol; 2009 Jun;29(3):173-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is an aggressive neoplasm with a high tendency for late recurrence and occasional delayed distant metastasis.
  • CASE REPORT: A 14-year-old boy without a past medical history presented with a 1-month history of progressive proptosis on the right eye.
  • Computed tomography (CT) scans of the orbit revealed a right intraconic lesion, with areas of calcification.
  • Histopathological analysis revealed that the tumor had a biphasic pattern, showing a combination of small cell malignancy and well-differentiated cartilage.
  • Immunohistochemistry examination revealed a diffuse membrane expression of CD99 on the small cell malignancy; S-100 was positive only within the cartilage component.
  • The patient received chemotherapy, and no metastatic disease was found at the 2-month follow-up.
  • CONCLUSION: Although rare, MC should be considered in the differential diagnosis of a well-circumscribed orbital lesion in young adults, especially when CT scans reveal areas of calcification within the tumor.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Antigens, CD / biosynthesis. Antigens, CD99. Calcinosis / diagnosis. Cartilage / metabolism. Cartilage / pathology. Cell Adhesion Molecules / analysis. Cell Adhesion Molecules / biosynthesis. Diagnosis, Differential. Drug Therapy. Humans. Immunohistochemistry. Male. Mesenchymal Stromal Cells / metabolism. Mesenchymal Stromal Cells / pathology. S100 Proteins / analysis. S100 Proteins / biosynthesis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1999 Jul;52(1):50-3 [10390173.001]
  • [Cites] Histopathology. 2006 Jan;48(2):201-3 [16405671.001]
  • [Cites] Cancer. 1971 Sep;28(3):605-15 [5096926.001]
  • [Cites] Neuroradiology. 1997 Apr;39(4):296-301 [9144681.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2006 Sep-Oct;22(5):378-82 [16985424.001]
  • [Cites] Skeletal Radiol. 2005 Dec;34(12 ):785-92 [16211384.001]
  • [Cites] Radiol Clin North Am. 1999 Jan;37(1):203-17, xii [10026739.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):192-204 [17284103.001]
  • [Cites] Laryngoscope. 2003 May;113(5):783-90 [12792311.001]
  • [Cites] Ophthalmology. 2004 May;111(5):1016-22 [15121382.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Jul-Aug;13(4):1253-5 [1636546.001]
  • [Cites] Cancer. 1986 Jun 15;57(12 ):2444-53 [3697943.001]
  • [Cites] Cancer. 1959 Nov-Dec;12:1142-57 [14416919.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1088-94 [15731776.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):263-9 [12673561.001]
  • (PMID = 18188507.001).
  • [ISSN] 1573-2630
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD99; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / S100 Proteins
  •  go-up   go-down


8. Kowalzick L, Rogozinski T, Wimheuer R, Pilz J, Manske U, Scholz A, Fierlbeck G, Mohr P, Ochsendorf F, Wagner G, Gaus W, Brzoska J, Jablonska S: Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study. Eur J Dermatol; 2002 Nov-Dec;12(6):558-61
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study.
  • Although effective conventional therapies are available to treat basal cell carcinoma (BCC), undesirable side effects, including scarring, and in some cases permanent damage, often occur in problematic areas of the body, especially around the eyes, mouth, and cartilage of the nose and ears.
  • Secondary objectives included evaluating the effect of tumour type/size on response as well as residues, cosmetic results, and relapse rate after CR.
  • Intratumoural injections of rIFN-beta-1a (1.0 x 106 IU) were administered three times a week for 3 weeks.
  • The response was determined 16 weeks after start of treatment and the status of patients was followed for up to 5 years.
  • There was no significant difference between the response rates for patients with solid or other BETACC tumour types.
  • Similarly, tumour size did not significantly affect the response rate.
  • The cosmetic result of treatment was rated as good or very good in 83% of responders.
  • All patients showed local inflammatory reactions, which were generally considered to be the adverse drug reactions (ADRs).
  • These results show that intratumoural injections of rIFN-beta-1a are effective in the treatment of BETACC in the majority of patients.
  • In addition, rIFN-beta-1a is safe and generally well tolerated. rIFN-beta-1a represents an effective alternative treatment for BETACC.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / drug therapy. Interferon Type I / administration & dosage. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Needle. Confidence Intervals. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Injections, Intralesional. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459527.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Interferon Type I; 0 / Recombinant Proteins
  •  go-up   go-down


9. Franco RA Jr, Singh B, Har-El G: Laryngeal chondroma. J Voice; 2002 Mar;16(1):92-5
Genetic Alliance. consumer health - Chondroma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cartilaginous tumors of the larynx represent less than 1% of laryngeal tumors.
  • Chondroma and "low-grade" chondrosarcoma are the most common; 70%-75% of these tumors arise on the endolaryngeal surface of the posterior lamina of the cricoid cartilage.
  • The clinical presentation is varied and directly dependent on the size and location of the tumor; stridor, hoarseness, dyspnea, or a neck mass are common presenting signs.
  • CT scanning in the axial plane is the mainstay of radiographic imaging due to its ability to show size, extent of the tumor, and invasion into surrounding structures.
  • Surgical extirpation is the standard therapy with no role for radiation therapy or chemotherapy.
  • Although significant recurrence rates have been reported, there is not a significant difference between initial conservative therapy followed by salvage therapy versus initial radical therapy.
  • [MeSH-major] Chondroma / radiography. Laryngeal Neoplasms / radiography
  • [MeSH-minor] Aged. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12008653.001).
  • [ISSN] 0892-1997
  • [Journal-full-title] Journal of voice : official journal of the Voice Foundation
  • [ISO-abbreviation] J Voice
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Wiesenthal AA, Nguyen BD: F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions. Clin Nucl Med; 2007 Oct;32(10):797-801
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma is the most common plasma cell neoplasm, with abnormal clonal proliferation of B cells in bone marrow.
  • Its staging is important for therapeutic management and prognosis.
  • Through imaging integration, PET provides functional detection of high metabolic lesions whereas CT provides correlated anatomic localization.
  • The authors present a case of multiple myeloma status post chemotherapy and stem cell transplant with diffuse osseous and extramedullary lesions evaluated by PET/CT.
  • The extramedullary involvement concerns the maxillary sinus, thyroid cartilage, mediastinum, retroperitoneum, neuroforamen, and epidura.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fluorodeoxyglucose F18. Multiple Myeloma / diagnosis. Positron-Emission Tomography / methods. Soft Tissue Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Subtraction Technique

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885362.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


11. Wycliffe ND, Grover RS, Kim PD, Simental A Jr: Hypopharyngeal cancer. Top Magn Reson Imaging; 2007 Aug;18(4):243-58
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopharyngeal cancer.
  • Overall, 5-year survival rate remains poor despite recent improvements in diagnostic imaging, radiation and chemotherapy, and improved surgical techniques.
  • Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) remain the mainstay of initial radiological evaluation of hypopharyngeal cancer.
  • Imaging usually results in upstaging of the tumor at presentation.
  • Meticulous evaluation of the extent of the primary tumor with attention to spread to the subsites of the hypopharynx, larynx, and cartilage invasion are necessary for accurate staging.
  • After surgery and radiation therapy, it is difficult with CT and MR to differentiate residual and recurrent tumor from edema and scarring.
  • Fluorine 18-fluoro-deoxy-glucose -positron emission tomography (FDG-PET) has high sensitivity in detection of occult, residual, and recurrent tumors but has low specificity.
  • [MeSH-major] Hypopharyngeal Neoplasms / diagnosis. Hypopharyngeal Neoplasms / radiography. Hypopharynx / pathology. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Hypopharyngeal cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17893590.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 138
  •  go-up   go-down


12. Argani P, Beckwith JB: Metanephric stromal tumor: report of 31 cases of a distinctive pediatric renal neoplasm. Am J Surg Pathol; 2000 Jul;24(7):917-26
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric stromal tumor: report of 31 cases of a distinctive pediatric renal neoplasm.
  • We report 31 cases of a novel pediatric renal neoplasm, metanephric stromal tumor (MST).
  • Gross examination typically revealed a fibrous lesion centered in the renal medulla containing smooth-walled cysts (mean tumor size, 5.5 cm).
  • Characteristic histologic features of MST include alternating cellularity that imparts a nodular low-power appearance, onion-skin cuffing around entrapped renal tubules, heterologous differentiation (glia or cartilage), and vascular alterations (angiodysplasia of entrapped arterioles, juxtaglomerular cell hyperplasia in entrapped glomeruli).
  • Three tumors in which the vascular alterations were particularly florid were associated with extrarenal vasculopathy and attendant morbidity.
  • Recognition of this entity can spare a child potentially toxic adjuvant chemotherapy that might be used for lesions in its differential diagnosis, specifically clear cell sarcoma of the kidney.
  • [MeSH-major] Kidney Neoplasms / pathology. Neoplasms, Germ Cell and Embryonal / pathology. Nephroma, Mesoblastic / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Male. Stromal Cells / chemistry. Stromal Cells / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895814.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-42386
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


13. Hill DA, Jarzembowski JA, Priest JR, Williams G, Schoettler P, Dehner LP: Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry. Am J Surg Pathol; 2008 Feb;32(2):282-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry.
  • Pleuropulmonary blastoma (PPB) is a malignant neoplasm of the lung that presents in early childhood.
  • The early form of the disease, cystic type I PPB, can be clinically and pathologically deceptive because of its resemblance to some developmental lung cysts.
  • This study reviews 51 cases of type I PPB and 6 lung cysts from relatives of children with PPB.
  • Type I PPB is a delicate multilocular cyst with variable numbers of primitive mesenchymal cells beneath a benign epithelial surface.
  • Rhabdomyoblasts and cartilage nodules are seen in 49% and 40% of cases, respectively.
  • Tumors in the youngest subset of patients, from birth to 2 months of age, are more uniform in composition and cellularity compared with those in older groups.
  • Early tumors have a subtle transition between normal developing lung and tumor, showing bland interstitial mesenchymal cells uniformly expanding the alveolar septa.
  • This phenomenon may explain the variable and sometimes sparse tumor cellularity seen in some type I PPBs.
  • On a biologic level, this process supports the concept that not all type I PPBs are fated to progress to a type II or III PPB.
  • Factors that control the balance between progression and regression may be important in predicting tumor behavior and determining which patients will benefit from adjuvant chemotherapy.
  • In the meantime, recognition of this lesion as a neoplasm with malignant potential rather than a developmental cystic malformation is vital so the child can receive complete excision and appropriate follow-up care.
  • [MeSH-major] Cystic Adenomatoid Malformation of Lung, Congenital / pathology. Lung Neoplasms / pathology. Pleural Neoplasms / pathology. Pulmonary Blastoma / pathology
  • [MeSH-minor] Age Factors. Child. Child, Preschool. Combined Modality Therapy. Cysts / pathology. Diagnosis, Differential. Family Health. Female. Genetic Predisposition to Disease. Humans. Infant. Infant, Newborn. International Cooperation. Male. Registries


14. Ferreti Bonan PR, Nogueira Dos Santos LA, Batista De-Paula AM, Coletta RD, Martelli Jùnior H: Chondrosarcoma involving the periodontum: clinicopathological and immunohistochemical features of a case study. Minerva Stomatol; 2006 Oct;55(10):587-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondrosarcoma is a rare flat bone neoplasm.
  • The histopathological features showed atypical cartilage arranged in lobules compatible with chondrosarcoma.
  • Immunohistochemistry showed that tumor cells were immunoreactive for the anti-vimentin and S-100 antibodies.
  • Moreover, no tumor cells had been immunostained by anti-p53.
  • Treatment consisted of chemotherapy, followed by radical surgery and postsurgery treatment with an association of radio and chemotherapy.
  • [MeSH-major] Chondrosarcoma / pathology. Gingival Neoplasms / pathology. Mandibular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Remission Induction

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268393.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 15
  •  go-up   go-down


15. Craver RD, Lipscomb JT, Suskind D, Velez MC: Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol; 2001 Oct;5(5):285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Loose myxoid tissue resembled primitive cartilage.
  • The tumor from the left and right thyroid lobes exhibited trisomy 8, the right also had hyperdiploid cell lines.
  • She was treated with aggressive combination chemotherapy and radiation.
  • Presently there is no residual disease 16 months after diagnosis.
  • Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis.
  • Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease.
  • The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor.
  • Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma.
  • Therapy should be tailored to the management of all transformed histologies.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Aneuploidy. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Image Cytometry. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11598856.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 34
  •  go-up   go-down


16. Verdegaal SH, Corver WE, Hogendoorn PC, Taminiau AH: The cytotoxic effect of phenol and ethanol on the chondrosarcoma-derived cell line OUMS-27: an in vitro experiment. J Bone Joint Surg Br; 2008 Nov;90(11):1528-32
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgery is considered to be the most effective treatment for cartilaginous tumours.
  • In recent years, a trend has emerged for patients with low-grade tumours to be treated less invasively using curettage followed by various forms of adjuvant therapy.
  • Using a human chondrosarcoma-derived cartilage-producing cell line OUMS-27 as an in vitro model we studied the cytotoxic effect of phenol and ethanol.
  • These results may provide a clinical rationale for the use of both phenol and ethanol as adjuvant therapy after intralesional curettage in low-grade central chondrosarcoma and justify further investigation.
  • [MeSH-major] Chondrosarcoma / drug therapy. Cytotoxins / therapeutic use. Ethanol / therapeutic use. Phenol / therapeutic use
  • [MeSH-minor] Cell Line. Chemotherapy, Adjuvant. Curettage. Humans. Statistics as Topic

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Hazardous Substances Data Bank. PHENOL .
  • Hazardous Substances Data Bank. SODIUM PHENOLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18978278.001).
  • [ISSN] 0301-620X
  • [Journal-full-title] The Journal of bone and joint surgery. British volume
  • [ISO-abbreviation] J Bone Joint Surg Br
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytotoxins; 339NCG44TV / Phenol; 3K9958V90M / Ethanol
  •  go-up   go-down


17. Kaur A, Kishore P, Agrawal A, Gupta A: Mesenchymal chondrosarcoma of the orbit: a report of two cases and review of the literature. Orbit; 2008;27(1):63-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesenchymal chondrosarcoma, an uncommon lesion in bone and extraskeletal tissue, is extremely rare in the orbit.
  • The diagnosis was established by histopathological examination in both cases, which showed undifferentiated mesenchymal cells with islands of cartilage.
  • Both patients underwent exenteration followed by chemotherapy and radiation therapy and are alive with healthy orbits after two years of follow-up.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Neoplasm Recurrence, Local / therapy. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Female. Humans. Male. Orbit Evisceration. Radiotherapy, Adjuvant. Reoperation. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307151.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VAC protocol
  • [Number-of-references] 11
  •  go-up   go-down


18. Salamanca J, Dhimes P, Pinedo F, Gómez de la Fuente E, Pérez Espejo G, Martínez-Tello FJ: Extraskeletal cutaneous chondroblastic osteosarcoma: a case report. J Cutan Pathol; 2008 Feb;35(2):231-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extraskeletal osteosarcoma is an uncommon neoplasm that usually arises in the deep soft tissues, especially in the lower extremities, with rare cases involving the subcutis or dermis.
  • An incisional skin biopsy showed a well-defined, but non-encapsulated neoplasm, characterized by extensive cartilage with marked cellularity, atypia and high mitotic activity, involving the dermis and subcutis.
  • Although osteoid or bone was not observed, a diagnosis of cutaneous chondroblastic osteosarcoma was suggested after excluding an origin in bone or other primary tumor sites by imaging techniques.
  • Histopathologic features of the surgical specimen were characteristic, with a predominant high-grade chondroid component together with focal fibrosarcomatous zones, areas of multinucleated giant cells and foci of bone and osteoid formation.
  • The patient underwent postoperative chemotherapy and is currently alive with pulmonary metastases 15 months after surgery.
  • In summary, we report a unique case of cutaneous osteosarcoma of the chondroblastic subtype, diagnosed on incisional skin biopsy despite the absence of osteoid or bone during tumor sampling.
  • [MeSH-major] Osteosarcoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Thigh / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190451.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


19. Kotil K, Bilge T, Olagac V: Primary intradural myxoid chondrosarcoma: a case report and review in the literature. J Neurooncol; 2005 Nov;75(2):169-72
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE AND IMPORTANCE: Chondrosarcomas are extremely rare cartilaginous tumours that typically usually are associated with bone.
  • Therapeutic experience with primary spinal mesenchymal chondrosarcomas is also extremely limited.
  • Magnetic resonance imaging (MRI)demonstrated at the T12 level intradural tumour.
  • INTERVENTION: At surgery, a mass found attached solely to pia mater, with a normal arachnoid and dura mater overlying was seen.
  • CONCLUSION: The differential diagnosis considered in the present case included meningioma, plasmacytoma, and non-neoplastic intradural spinal cord lesion.
  • We emphasize the benefit of surgical resection without radiotherapy and/or chemotherapy.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / diagnosis. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Pia Mater / pathology
  • [MeSH-minor] Adult. Dura Mater / surgery. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Radiography. Time Factors. Treatment Outcome. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Aug;40(2):818-31 [890662.001]
  • [Cites] J Neurosurg. 1994 May;80(5):928-30 [8169637.001]
  • [Cites] Surg Neurol. 1989 Jun;31(6):470-2 [2718090.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):828-34 [8636311.001]
  • [Cites] Clin Orthop Relat Res. 1982 Jun;(166):226-32 [7083677.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):420-3 [11220388.001]
  • [Cites] Clin Orthop Relat Res. 1993 Sep;(294):90-5 [8358950.001]
  • [Cites] Spine (Phila Pa 1976). 1978 Sep;3(3):202-9 [715548.001]
  • [Cites] Clin Neuropathol. 1995 May-Jun;14(3):150-3 [7671456.001]
  • [Cites] Cancer. 1986 Jun 15;57(12 ):2444-53 [3697943.001]
  • (PMID = 16283441.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  •  go-up   go-down


20. Aoki J: [Roles of magnetic resonance imaging in management of bone tumors]. Nihon Igaku Hoshasen Gakkai Zasshi; 2000 May;60(6):295-301
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Roles of magnetic resonance imaging in management of bone tumors].
  • The roles of magnetic resonance imaging (MRI) in the diagnosis and treatment of bone tumors are reviewed.
  • Most bone tumors can be detected on plain radiography or bone scintigraphy.
  • MRI is helpful in detecting tumors that do not destroy bone matrix or suppress reactive bone formation.
  • Detailed analysis by plain radiography is still the most reliable method for differentiating between benign and malignant bone tumors.
  • In characterizing the histologic types of bone tumors, MRI is of some advantage.
  • For example, MRI can demonstrate cartilage matrix, hemoglobin metabolites, vascular components, and fat contents more clearly than conventional radiological techniques.
  • MRI is now indispensable for the preoperative delineation of malignant bone tumors, because of its excellent soft tissue contrast and multiplanar imaging capability.
  • In this article, the guidelines for evaluation of the surgical margin advocated by the JOA Musculo-skeletal Tumor Committee are introduced for radiologists.
  • MRI monitoring of malignant bone tumors after chemotherapy or surgery can reveal change in the size of enhanced areas that may reflect viable tumors.
  • Dynamic MRI is helpful to differentiate recurrent tumors from granulation tissue.
  • [MeSH-major] Bone Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10860379.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Number-of-references] 23
  •  go-up   go-down


21. Rodriguez CP, Adelstein DJ, Rybicki LA, Saxton JP, Lorenz RR, Wood BG, Strome M, Esclamado RM, Lavertu P, Carroll MA: Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck; 2008 Dec;30(12):1535-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cisplatin and fluorouracil were given during weeks 1 and 4 of radiation to 115 patients with locoregionally advanced larynx or hypopharynx squamous cell cancer without cartilage invasion or laryngeal destruction.
  • Local control without surgery was superior in patients with T1-2 versus T3-4 tumors (97% vs 77%, p = .032).
  • Although local failure was more likely in patients with T3-4 tumors, it was infrequent and surgical salvage was effective.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Neoplasms, Squamous Cell / drug therapy. Neoplasms, Squamous Cell / radiotherapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Hypopharyngeal Neoplasms / drug therapy. Hypopharyngeal Neoplasms / radiotherapy. Kaplan-Meier Estimate. Laryngectomy. Male. Middle Aged. Patient Participation. Patient Selection. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc.
  • (PMID = 18704968.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. McLoughlin GS, Sciubba DM, Wolinsky JP: Chondroma/Chondrosarcoma of the spine. Neurosurg Clin N Am; 2008 Jan;19(1):57-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondromas and chondrosarcomas are cartilage-forming tumors that occur rarely in the spine.
  • These neoplasms exist on opposite ends of the pathologic spectrum, ranging from the benign chondroma to the malignant, high-grade chondrosarcoma.
  • Unlike other sarcomas, a patient's long-term prognosis is influenced by the grade of the tumor.
  • These tumors are resistant to conventional chemotherapy and radiation therapy.
  • Hypofractionated stereotactic radiation therapy may slow tumor progression, although the long-term effect of this modality is unknown.
  • [MeSH-major] Chondroma / pathology. Chondroma / surgery. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Spinal Neoplasms / pathology. Spinal Neoplasms / surgery
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Neurosurgical Procedures / methods. Prognosis. Radiosurgery / methods. Radiotherapy / methods. Spine / pathology. Spine / surgery

  • Genetic Alliance. consumer health - Chondroma.
  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156048.001).
  • [ISSN] 1558-1349
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 49
  •  go-up   go-down


23. Ramos P, Ruiz A, Carabias E, Piñero I, Garzon A, Alvarez I: Müllerian adenosarcoma of the cervix with heterologous elements: report of a case and review of the literature. Gynecol Oncol; 2002 Jan;84(1):161-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Müllerian adenosarcoma (MA) is a rare neoplasm composed of benign epithelial and malignant stromal components.
  • We describe another case of MA of the uterine cervix with heterologous elements and review the clinical and pathological features of these tumors.
  • Microscopically, the last curettage performed revealed a tumor composed of two elements, epithelial and mesenchymal.
  • The epithelial elements were benign endocervical type glands, and the mesenchymal were sarcomatous, containing minor foci of cartilage.
  • A diagnosis of endocervical heterologous adenosarcoma was reached, and a total hysterectomy and bilateral salpingo-oophorectomy were performed.
  • The patient is alive 2 years after the surgical procedure.
  • Neither chemotherapy nor other adjuvant therapies have been administered, and she is clinically free of disease at the moment.
  • CONCLUSION: Because MA with heterologous elements seems to appear at the earliest stages of the reproductive lifespan in women, commonly with a history of recurrent polyps, and because its malignant potential is uncertain, gynecologists and pathologists should be aware and think about the possibility of this tumor.
  • Long-term follow-up is essential and so is the accumulation of individual cases to provide further experience with these unusual neoplasms.
  • [MeSH-major] Adenosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11748995.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


24. Benateau H, Rigau V, Martin JP, Labbé D, Compère JF: [Diagnostic difficulties of chondrosarcoma of the jaw. Apropos of a case and review of the literature]. Rev Stomatol Chir Maxillofac; 2000 Apr;101(2):80-5
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Difficultés diagnostiques du chondrosarcome des maxillaires. A propos d'un cas et revue de la littérature.
  • Chondrosarcoma is an uncommon malignant mesenchymal tumor characterized by the production of cartilaginous tissue and the absence of production of bone tissue.
  • The clinical and radiographic findings are similar to those seen in other tumors of the jaw, often delaying diagnosis and treatment and subsequently jeopardizing prognosis.
  • In the literature, the mean delay from first clinical signs to diagnosis is about 8 months.
  • As in all tumoral diseases, pathology confirms the diagnosis.
  • We report a case of chondrosarcoma of the maxillary bone and review the literature, focusing on the difficulty in establishing the diagnosis, even at the pathology examination.
  • We propose wide surgical excision, which, in agreement with other reports in the literature, is the only therapeutic possibility.
  • Radiotherapy and chemotherapy may be useful in certain cases.
  • [MeSH-major] Chondrosarcoma / diagnosis. Mandibular Neoplasms / diagnosis
  • [MeSH-minor] Adult. Bone and Bones / pathology. Cartilage / pathology. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Mandible / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10859759.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 40
  •  go-up   go-down






Advertisement